SCHEMBL1734129

SCHEMBL1734129

C=CCNc1nc(C(N)=O)cc(-c2cccc(OC)c2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VCP P55072 3/20 0.48
ADORA1 P30542 4/20 0.44
ADORA2A P29274 4/20 0.44
ADORA3 P0DMS8 2/20 0.44
ADORA2B P29275 2/20 0.44
MAPT P10636 5/20 0.43
IRAK4 Q9NWZ3 1/20 0.42
HTT P42858 2/20 0.42
HSD17B10 Q99714 2/20 0.42
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
IKBKB O14920 1/20 0.42
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
CYP1A2 P05177 1/20 0.41
GAA P10253 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1733597 0.88 TP53 (0.51) VCPADORA3ADORA2BMAPTKDM4E
SCHEMBL1734123 0.87 VCP (0.51) VCPADORA1ADORA2AADORA3ADORA2B
SCHEMBL1734170 0.84 VCP (0.51) VCPADORA1ADORA2AADORA3ADORA2B
SCHEMBL1733359 0.83 ADORA1 (0.50) VCPADORA1ADORA2AADORA3ADORA2B
SCHEMBL1734512 0.83 VCP (0.48) VCPADORA1ADORA2AADORA3ADORA2B
SCHEMBL1734639 0.82 VCP (0.70) VCP
SCHEMBL1734586 0.81 KDM4E (0.66) VCPADORA1ADORA2AADORA3ADORA2B
SCHEMBL1734652 0.80 VCP (0.46) VCPADORA1ADORA2AADORA3MAPT
SCHEMBL1733528 0.77 ADORA1 (0.60) ADORA1ADORA2AADORA3ADORA2BIKBKB
SCHEMBL1734655 0.77 NPC1 (0.58) VCPMAPTHTTHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1891018-B1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2011-11-16 EP claimed
WO-2011131686-A1 A THERMALLY CONTROLLED ASSEMBLY NAPATECH A/S (DK) 2011-10-27 WO claimed
EP-1891018-A2 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS Vertex Pharmaceuticals, Inc. (US) 2008-02-27 EP claimed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US claimed
WO-2006127588-A2 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-11-30 WO claimed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105833-A1 Modulators of ATP-binding cassette transporters ABCC4, CFTR, ABCC2 VCP 224/4885ADORA1 142/4885ADORA2A 161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.